In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite

키워드

참고문헌 (33)

1. Alvar J, "Leishmaniasis worldwide and global estimates of its incidence", PLoS One, 7, pp.e35671~ (2012)
2. Papadopoulou B, "Stage-specific regulation of gene expression in Leishmania", ASM News, American Society for Microbiology, 69, pp.282~288 (2003)
3. Gantt KR, "Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi", J Immunol, 167, pp.893~901 (2001)
4. Garg R, "Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani", Clin Exp Immunol, 140, pp.149~156 (2005)
5. Holzmuller P, "Nitric oxide-mediated proteasome-dependent oligonucleosomal DNA fragmentation in Leishmania amazonensis amastigotes", Infect Immun, 70, pp.3727~3735 (2002)
6. Sharma U, "Immunobiology of leishmaniasis", Indian J Exp Biol, 47, pp.412~ (2009)
7. Kram D, "Intracellular parasite kill: flow cytometry and NO detection for rapid discrimination between anti-leishmanial activity and macrophage activation", J Immunol Methods, 333, pp.79~88 (2008)
8. Gupta S, "Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening", Antimicrob Agents Chemother, 49, pp.3776~3783 (2005)
9. Rocha MN, "An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein", Diagn Microbiol Infect Dis, 75, pp.282~291 (2013)
10. Avlonitis N, "Antileishmanial ring-substituted ether phospholipids", J Med Chem, 46, pp.755~767 (2003)
11. Mikus J, "A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue®", Parasitol Int, 48, pp.265~269 (2000)
12. Bodley AL, "Drug cytotoxicity assay for African trypanosomes and Leishmania species", J Infect Dis, 172, pp.1157~1159 (1995)
13. Croft S, "In vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasis", Parasitol Today, 2, pp.64~69 (1986)
14. Gupta S, "Visceral leishmaniasis: experimental models for drug discovery", Indian J Med Res, 133, pp.27~ (2011)
15. Lang T, "Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice", Cell Microbiol, 7, pp.383~392 (2005)
16. Dube A, "Reporter genes facilitating discovery of drugs targeting protozoan parasites", Trends Parasitol, 25, pp.432~439 (2009)
17. Naylor LH, "Reporter gene technology: the future looks bright", Biochem Pharmacol, 58, pp.749~757 (1999)
18. Monzote L, "Current treatment of leishmaniasis: a review", Open Antimicrob Agnts J, 1, pp.9~19 (2009)
19. Bolhassani A, "Fluorescent Leishmania species: Development of stable GFP expression and its application for in vitro and in vivo studies", Exp Parasitol, 127, pp.637~645 (2011)
20. Gangwar S, "Development of luciferase expressing Leishmania donovani axenic amastigotes as primary model for in vitro screening of antileishmanial compounds", Curr Microbiol, 65, pp.696~700 (2012)
21. Wu Y, "A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication", Virus Res, 155, pp.406~414 (2011)
22. Vaughan AM, "A transgenic Plasmodium falciparum NF54 strain that expresses GFP-luciferase throughout the parasite life cycle", Mol Biochem Parasitol, 186, pp.143~147 (2012)
23. Taheri T, "Generation of stable L. major+EGFP-LUC and simultaneous comparison between EGFP and luciferase sensitivity", Exp Parasitol, 150, pp.44~55 (2015)
24. Jain SK, "A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line", J Vis Exp, (70), pp.e4054~ (2012)
25. Michel G, "Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro", PLoS Negl Trop Dis, 5, pp.e1323~ (2011)
26. Mehta SR, "Flow cytometric screening for anti-leishmanials in a human macrophage cell line", Exp Parasitol, 126, pp.617~620 (2010)
27. Ploemen IH, "Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging", PLoS One, 4, pp.e7881~ (2009)
28. Shio MT, "Editorial: Leishmania survival mechanisms: the role of host phosphatases", J Leukoc Biol, 88, pp.1~3 (2010)
29. Balestieri F, "Leishmania (L.) amazonensis-induced inhibition of nitric oxide synthesis in host macrophages", Microb Infect, 4, pp.23~29 (2002)
30. Pearson R, "Failure of the phagocytic oxidative response to protect human monocyte-derived macrophages from infection by Leishmania donovani", J Immunol, 129, pp.1282~1286 (1982)
31. Paloque L, "A new, rapid and sensitive bioluminescence assay for drug screening on Leishmania", J Microbiol Methods, 95, pp.320~323 (2013)
32. Sereno D, "DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening", Antimicrob Agents Chemother, 45, pp.1168~1173 (2001)
33. Reimão JQ, "Parasite burden in Leishmania (Leishmania) amazonensis-infected mice: validation of luciferase as a quantitative tool", J Microbiol Methods, 93, pp.95~101 (2013)

관련 논문AI추천